Early responses to nonconjugated polyribosylribitol phosphate challenge as evidence of immune memory after combined diphtheria-tetanus-pertussis-polio-Haemophilus influenzae type b primary vaccination

Pediatric Infectious Disease Journal

Volumn 20, Issue 6, 2001, Pages 587-592

  Dagan, Ron ^a   Amir, Jacob ^b   Ashkenazi, Shay ^b   Hardt, Karin ^c   Kaufhold, Achim ^c  

^a BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

^b SCHNEIDER CHILDREN S MEDICAL CENTER OF ISRAEL   (Israel)

^c GLAXOSMITHKLINE BIOLOGICALS   (Belgium)

Author keywords

Acellular pertussis vaccine; Combination vaccine; Haemophilus influenzae type b; Immune memory; Immune response

Indexed keywords

ANTIBODY; BACTERIAL ANTIGEN; DIPHTHERIA PERTUSSIS POLIOMYELITIS TETANUS VACCINE; HAEMOPHILUS INFLUENZAE TYPE B VACCINE; HEPATITIS A VACCINE; POLYRIBOSYLRIBITOL PHOSPHATE; POLYRIBOSYLRIBITOL PHOSPHATE ANTIBODY; UNCLASSIFIED DRUG;

ANTIBODY BLOOD LEVEL; ARTICLE; BACTERIAL INFECTION; CONTROLLED STUDY; HAEMOPHILUS INFLUENZAE TYPE B; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; IMMUNOLOGICAL MEMORY; INFANT; INFECTION PREVENTION; INFECTION RISK; NORMAL HUMAN; PRIORITY JOURNAL; PROVOCATION TEST; TIME; VACCINATION;

ANTIBODIES, BACTERIAL; ANTIBODIES, VIRAL; ANTIBODY FORMATION; DIPHTHERIA-TETANUS-ACELLULAR PERTUSSIS VACCINES; DOSE-RESPONSE RELATIONSHIP, IMMUNOLOGIC; DRUG ADMINISTRATION SCHEDULE; FEMALE; HAEMOPHILUS VACCINES; HUMANS; IMMUNOLOGIC MEMORY; INFANT; MALE; POLIOVIRUS VACCINE, INACTIVATED; POLYSACCHARIDES; POLYSACCHARIDES, BACTERIAL; TIME FACTORS;

EID: 0034977222     PISSN: 08913668     EISSN: None     Source Type: Journal    
DOI: 10.1097/00006454-200106000-00008     Document Type: Article

References (38)

1. Induction of immunological memory in infants primed with Haemophilus influenzae type b conjugate vaccines
2. Priming and induction of Haemophilus influenzae type b capsular antibodies in early infancy by Dpo 20, an oligosaccharide-protein conjugate vaccine
3. Laboratory correlates of protection against Haemophilus influenzae type b disease: Importance of assessment of antibody avidity and immunological memory
4. High antibody responses to booster doses of either Haemophilus influenzae capsular polysaccharide or conjugate vaccine after primary immunization with conjugate vaccines
5. Avidity maturation of antibody to Haemophilus influenzae type b (Hib) after immunization with diphtheria-tetanus-acellular pertussis-Hib-hepatitis B combined vaccine in infants
6. Antibody avidity as a surrogate marker of successful priming by Haemophilus influenzae type b conjugate vaccines following infant immunization
7. Analysis of Haemophilus influenzae type b conjugate and diphtheria-tetanus-pertussis combination vaccines
8. Evidence for induction of polysaccharide specific B-cell-memory in the first year of life: Plain Haemophilus influenzae type b PRP (Hib) boosters in children primed with a tetanus-conjugate Hib-DTPa-HBV combined vaccine
9. Immunogenicity and reactogenicity of a Haemophilus influenzae type b tetanus conjugate vaccine when administered separately or mixed with concomitant diphtheria-tetanus-toxoid and acellular pertussis vaccine for primary and for booster immunizations
10. Priming effect, immunogenicity and safety of an Haemophilus Influenzae type b-tetanus toxoid conjugate (PRP-T) and diphtheria-tetanus-acellular pertussis (DTaP) combination vaccine administered in Belgium and Turkey
11. Safety and immunogenicity of Haemophilus influenzae tetanus toxoid conjugate vaccine given separately or in combination with a three component acellular pertussis vaccine combined with diphtheria and tetanus toxoids and inactivated poliovirus vaccine for the first four doses
12. Administration of combined diphtheria and tetanus toxoid and pertussis vaccine, hepatitis B vaccine and Haemophilus influenzae type b (Hib) vaccine to infants and response to a booster dose of Hib conjugate vaccine
13. The induction of immunological memory after vaccination with Haemophilus influenzae type b conjugate and acellular pertussis-containing diphtheria, tetanus and pertussis vaccine combination
14. Haemophilus influenzae type b (Hib) conjugate vaccines administered in combination with DTP containing acellular pertussis and protection against invasive Hib disease
15. Update vaccine side effects, adverse reactions, contraindications, and precautions
16. Factors influencing immunogenicity and safety of two Haemophilus influenzae type b polysaccharide vaccines in children 18 and 24 months of age
17. Immunogenicity and reactogenicity of four Haemophilus influenzae type b capsular polysaccharide vaccines in Finnish 24-month-old children
18. Safety and immunogenicity of Haemophilus influenzae type b polysaccharide and polysaccharide diphtheria toxoid conjugate vaccines in children 15 to 24 month of age
19. Polysaccharide vaccines of Group A Neisseria meningitidis and Haemophilus influenzae type b: A field trial in Finland
20. Acquisition of "natural" and immunization-induced immunity to Haemophilus influenzae type b diseases
21. Serum anti-bodies after vaccination with Haemophilus influenzae type b capsular polysaccharide and responses to reimmunization: No evidence of immunologic tolerance or memory
22. Hemophilus B (HIB) vaccine in infants
23. Reimmunization of children immunized at 18 months of age with Haemophilus influenzae type b vaccine
24. Safety and immunogenicity of subcutaneous H. influenzae vaccines in 15-17 month-old children
25. Immunization with Haemophilus influenzae type b polysaccharide vaccine at 18 and 24 months of age: Evidence of decreased immunogenicity
26. Tolerance et immunogénicité du vaccin polyosidique capsulaire anti-Haemophilus influenzae type b
27. Isotype distribution and bactericidal activity of antibodies after immunization with Haemophilus influenzae type b vaccines at 18 to 24 months of age
28. Haemophilus b polysaccharide vaccine: Antibody kinetics in 17- to 71-month-old children
29. Antibody response of 18-month-old children 1 month and 18 months following Haemophilus influenzae type b vaccine administered singly or with DTP vaccine
30. Type b Haemophilus influenzae infections in adults
31. Capsular antigens or noncovalently associated with protein as vaccines to Haemophilus influenzae type b: Comparison in two-year-old children
32. Impaired antibody response to Haemophilus influenzae type b polysaccharide and low IgG2 and IgG4 concentrations in Apache children
33. Prospective comparison of the immune response of infants to three Haemophilus influenzae type b vaccines
34. Safety and immunogenicity of Haemophilus influenzae b-tetanus toxoid conjugate vaccine, mixed in the same syringe with diphtheria-tetanus-pertussis vaccine in young infants
35. Safety and immunogenicity of Haemophilus influenzae b-tetanus protein conjugate vaccine, mixed in the same syringe with diphtheria-tetanus-pertussis-enhanced inactivated poliovirus vaccine in young infants
36. Immunogenicity and safety of a liquid combination of DTP-PRT-T vs. lyophilized PRP-T reconstituted with DTP
37. Safety and immunogenicity of a combined pentavalent diphtheria, tetanus, acellular pertussis, inactivated poliovirus and Haemophilus influenzae type b-tetanus conjugate vaccine in infants, compared with a whole-cell pertussis pentavalent vaccine
38. Immunological memory and protective immunity: Understanding their relation